November 12, 2014
Author Address: From the *Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; daggerDepartment of Surgery, Karolinska Institute, Stockholm, Sweden; double daggerUnit of Nutrition, Environment and Cancer, Catalan Institute of Oncology, Barcelona, Spain; section signDepartments of Medicine and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; parallelDepartments of Medicine and Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN; paragraph signDepartment of Epidemiology, Mayo Graduate School of Medicine, Rochester, MN; and #Departments of Medicine, Cell Biology and Physiology, and Human Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Reference Type: Journal Article
Record Number: 4871Author: Andersson, B., Appelgren, B., Sjodin, V., Ansari, D., Nilsson, J., Persson, U., Tingstedt, B. and Andersson, R.
Title: Acute pancreatitis–costs for healthcare and loss of production
Journal: Scand J Gastroenterol
Short Title: Acute pancreatitis–costs for healthcare and loss of production
Alternate Journal: Scandinavian journal of gastroenterology
ISSN: 1502-7708 (Electronic)
Accession Number: 24131379
Keywords: Acute Disease
*Cost of Illness
Hospital Costs/*statistics & numerical data
Severity of Illness Index
Sick Leave/*economics/statistics & numerical data
Abstract: OBJECTIVE. Severity of acute pancreatitis (AP) can vary from a mild to a fulminant disease with high morbidity and mortality. Cost analysis has, however, hitherto been sparse. The aim of this study was to calculate the cost of acute pancreatitis, both including hospital costs and costs due to loss of production. MATERIAL AND METHODS. All adult patients treated at Skane University Hospital, Lund, during 2009-2010, were included. A severity grading was conducted and cost analysis was performed on an individual basis. RESULTS. Two hundred and fifty-two patients with altogether 307 admissions were identified. Mean age was 60 +/- 19 years, and 121 patients (48%) were men. Severe AP (SAP) was diagnosed in 38 patients (12%). Thirteen patients (5%) died. Acute biliary pancreatitis was more costly than alcohol induced AP (p < 0.001). Total costs for treating mild AP (MAP) in patients </=65 years old was lower (p = 0.001) and costs for SAP was higher (p = 0.024), as compared to older patients. The overall hospital cost and cost for loss of production was per person in mean euro5,100 +/- 2,400 for MAP and euro28,200 +/- 38,100 for SAP (p < 0.001). The costs for treating AP during the two-year-long study period were in mean euro9,762 +/- 19,778 per patient. Extrapolated to a national perspective, the annual financial burden for AP in Sweden would be euro38,500,000; corresponding to euro4,100,000 per million inhabitants. CONCLUSIONS. The costs of treating AP are high, especially in severe cases with a long ICU stay. These results highlight the need to optimize care and continue the identification and focus on SAP, in order to try to limit organ failure and infectious complications.